Drug Details
| General Information of the Drug (ID: DR0749) | ||||
|---|---|---|---|---|
| Name |
Sunitinib
|
|||
| Synonyms |
Sunitinibum; Sutent; PDGF TK antagonist; SU 11248; SU11248; KS-5022; SU-11248; SU-11248J; SU-12662; Su-011248; Sunitinib (INN); Sunitinib (free base); Sutent (TN); N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; 5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE; Sunitinib (Pan-TK inhibitor)
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Malignant digestive organ neoplasm [ICD-11: 2C11] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C22H27FN4O2
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C
|
|||
| InChI |
1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
|
|||
| InChIKey |
WINHZLLDWRZWRT-ATVHPVEESA-N
|
|||
| CAS Number |
CAS 557795-19-4
|
|||
| ChEBI ID | ||||
| GDSC | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Daunorubicin | Streptomyces peucetius | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | MV4-11 | CVCL_0064 | Childhood acute monocytic leukemia | Homo sapiens | ||
| Ba/F3 | CVCL_0161 | Healthy | Mus musculus | |||
| MOLM-14 | CVCL_7916 | Adult acute myeloid leukemia | Homo sapiens | |||
| Experimental
Result(s) |
The addition of potent FLT3 inhibitors such as SU11248 to AML chemotherapy regimens could result in improved treatment results. | |||||
| Gambogic acid | Garcinia morella | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
| Caki-1 | CVCL_0234 | Clear cell renal cell carcinoma | Homo sapiens | |||
| In-vivo Model | Caki-1 cells (2x106) in 100 ul RPMI-1640 and 100 ul of matrigel were used to inject subcutaneously into each mouse (5-week-old male athymic BALB/c nu/nu mice). | |||||
| Experimental
Result(s) |
The joint use of GA and SU can provide greater antitumor efficacy compared to either drug alone. | |||||
| β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Curcumin | Hellenia speciosa | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | CDK1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDK4 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor receptor 2 (KDR) | Molecule Info | [5] | |
| KEGG Pathway | Ras signaling pathway | Click to Show/Hide | ||
| 2 | Rap1 signaling pathway | |||
| 3 | Cytokine-cytokine receptor interaction | |||
| 4 | Endocytosis | |||
| 5 | PI3K-Akt signaling pathway | |||
| 6 | VEGF signaling pathway | |||
| 7 | Focal adhesion | |||
| 8 | Proteoglycans in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Angiogenesis | Click to Show/Hide | ||
| 2 | VEGF signaling pathway | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | Click to Show/Hide | ||
| 2 | Beta3 integrin cell surface interactions | |||
| 3 | Signaling events mediated by TCPTP | |||
| 4 | SHP2 signaling | |||
| 5 | S1P1 pathway | |||
| 6 | VEGF and VEGFR signaling network | |||
| 7 | Integrins in angiogenesis | |||
| 8 | Signaling events mediated by VEGFR1 and VEGFR2 | |||
| 9 | Notch-mediated HES/HEY network | |||
| Reactome | Neurophilin interactions with VEGF and VEGFR | Click to Show/Hide | ||
| 2 | VEGF binds to VEGFR leading to receptor dimerization | |||
| 3 | Integrin cell surface interactions | |||
| 4 | EPHA-mediated growth cone collapse | |||
| 5 | VEGFA-VEGFR2 Pathway | |||
| 6 | VEGFR2 mediated cell proliferation | |||
| WikiPathways | Focal Adhesion | Click to Show/Hide | ||
| 2 | Nifedipine Activity | |||
| 3 | Cardiac Progenitor Differentiation | |||
| 4 | Signaling by VEGF | |||
| 5 | Angiogenesis | |||
